FDA approval was definitive - new product increased revenue sp flies.
Vax result, good but not definitive - there is no increased revenue. it is actually an ongoing cost.
VAX needs - definitive results or a partner to sign up for the sp to fly.
While these results would be of interest, I don't think this it's enough to grab a partner. They will be waiting for the final numbers next year, just like Ian Frazer.
Let Frazer finish doing his thing, company can continue to focus on costs and sales. Its a numbers game for the next few quarters.
Ann: HSV-2 Interim Results Announcement-AHZ.AX, page-79
-
- There are more pages in this discussion • 153 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.14 |
Change
0.140(1.08%) |
Mkt cap ! $277.7M | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.50 | $13.14 | $559.5K | 42.05K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1180 | $13.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.35 | 500 | 1 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |